DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Levsin (Hyoscyamine Sulfate) - Indications and Dosage

 
 



INDICATIONS AND USAGE

Levsin® is effective as adjunctive therapy in the treatment of peptic ulcer. In acute episodes, Levsin® injection can be used to control gastric secretion, visceral spasm and hypermotility in spastic colitis, spastic bladder, cystitis, pylorospasm, and associated abdominal cramps. For use as adjunctive therapy in the treatment of irritable bowel syndrome (irritable colon, spastic colon, mucous colitis) and functional gastrointestinal disorders. Also as adjunctive therapy in the treatment of neurogenic bladder and neurogenic bowel disturbances (including the splenic flexure syndrome and neurogenic colon). Parenterally administered Levsin® is also effective in reducing gastrointestinal motility to facilitate diagnostic procedures such as endoscopy or hypotonic duodenography. Levsin® may be used to reduce pain and hypersecretion in pancreatitis, in certain cases of partial heart block associated with vagal activity, and as an antidote for poisoning by anticholinesterase agents.

  • IN ANESTHESIA:
  • Levsin® injection is indicated as a pre-operative antimuscarinic to reduce salivary, tracheobronchial, and pharyngeal secretions, to reduce the volume and acidity of gastric secretions, and to block cardiac vagal inhibitory reflexes during induction of anesthesia and intubation. Levsin® protects against the peripheral muscarinic effects such as bradycardia and excessive secretions produced by halogenated hydrocarbons and cholinergic agents such as physostigmine, neostigmine, and pyridostigmine given to reverse the actions of curariform agents.
  • IN UROLOGY:
  • Levsin® injection may also be used intravenously to improve radiologic visibility of the kidneys. It is also indicated along with morphine or other narcotics in symptomatic relief of biliary and renal colic.

DOSAGE AND ADMINISTRATION

The dose may be administered subcutaneously, intramuscularly, or intravenously without dilution. As with all parenteral drug products, Levsin® injection should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.

Gastrointestinal Disorders

The usual adult recommended dose is 0.5 to 1 mL (0.25 to 0.5 mg). Some patients may need only a single dose; others may require administration two, three, or four times a day at four hour intervals.

Diagnostic Procedures

The usual adult recommended dose is 0.5 to 1 mL (0.25 to 0.5 mg) administered intravenously 5 to 10 minutes prior to the diagnostic procedure.

Anesthesia

Adults and pediatric patients over 2 years of age

As a pre-anesthetic medication, the recommended dose is 5 g (0.005 mg) per kg of body weight. This dose is usually given thirty to sixty minutes prior to the anticipated time of induction of anesthesia or at the time the pre-anesthetic narcotic or sedatives are administered.

Levsin® injection may be used during surgery to reduce drug-induced bradycardia. It should be administered intravenously in increments of 0.25 mL and repeated as needed.

To achieve reversal of neuromuscular blockade, the recommended dose is 0.2 mg (0.4 mL) Levsin® injection for every 1 mg neostigmine or the equivalent dose of physostigmine or pyridostigmine.

HOW SUPPLIED

Levsin® injection (hyoscyamine sulfate injection USP, 0.5 mg/mL), is available in 1 mL ampuls.

  • 1 mL ampuls — Box of 5 NDC 68220-111-05

Store at controlled room temperature 15-30C (59-86F).

Also available as:

Levsin® Dosage
Strength
Package
Size
NDC
Tablets 0.125mg 100 68220-112-10
Tablets 0.125mg 500 68220-112-50
Sub-lingual Tablets 0.125mg 100 68220-113-10
Sub-lingual Tablets 0.125mg 500 68220-113-50
Elixir 0.125mg/5 mL Pint 0091-4532-16
Drops 0.125mg/mL 15mL 0091-4538-15
Injection 0.5mg/mL Box of 5-1mL 68220-111-05
Levbid® extended- 0.375mg 100 68220-115-10
release tablets 0.375mg 500 68220-115-50

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014